Literature DB >> 30701214

Understanding and quantifying the immune microenvironment in hepatocellular carcinoma.

Juan C Osorio1,2, James J Harding1,2.   

Abstract

Entities:  

Year:  2018        PMID: 30701214      PMCID: PMC6327173          DOI: 10.21037/tgh.2018.12.04

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


× No keyword cloud information.
  19 in total

1.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.

Authors:  Chunhong Zheng; Liangtao Zheng; Jae-Kwang Yoo; Huahu Guo; Yuanyuan Zhang; Xinyi Guo; Boxi Kang; Ruozhen Hu; Julie Y Huang; Qiming Zhang; Zhouzerui Liu; Minghui Dong; Xueda Hu; Wenjun Ouyang; Jirun Peng; Zemin Zhang
Journal:  Cell       Date:  2017-06-15       Impact factor: 41.582

2.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

3.  Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Hang Li; Ke Wu; Kaixiong Tao; Libo Chen; Qichang Zheng; Xiaoming Lu; Jun Liu; Liang Shi; Chuanqiao Liu; Guobin Wang; Weiping Zou
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 7.  Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Authors:  James J Harding; Imane El Dika; Ghassan K Abou-Alfa
Journal:  Cancer       Date:  2015-11-05       Impact factor: 6.860

Review 8.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

9.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.

Authors: 
Journal:  Cell       Date:  2017-06-15       Impact factor: 66.850

Review 10.  PD-L1 expression in human cancers and its association with clinical outcomes.

Authors:  Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

View more
  1 in total

1.  Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.

Authors:  Daniela Di Blasi; Tujana Boldanova; Lucia Mori; Luigi Terracciano; Markus H Heim; Gennaro De Libero
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-08-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.